Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.

Fiche publication

Date publication

janvier 2020


Bone marrow transplantation


Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier, Pr FORNECKER Luc-Matthieu

Tous les auteurs :
Hueso T, Gastinne T, Garciaz S, Tchernonog E, Delette C, Casasnovas RO, Durot E, Houot R, Tessoulin B, Tournilhac O, Malak S, Gyan E, Fornecker LM, Abraham J, Delapierre B, Peyrade F, Lemal R, Gressin R, Chantepie S, Borel C, Morello R, Bouabdallah K, Ibrahim A, Bouabdallah R, Le Gouill S, Damaj G


The combination of carmustine, etoposide, cytarabine, and melphalan (BEAM) as conditioning regimen prior to autologous stem-cell transplantation (ASCT) remains the standard of care for patients with mantle cell lymphoma (MCL) who are eligible for transplantation. The replacement of carmustine with bendamustine (BeEAM) was described as a promising alternative in non-Hodgkin lymphoma. The aim of this retrospective study was to compare the BeEAM with the BEAM regimen in MCL patients in the frontline setting. Sixty and 108 patients were included in the BeEAM and the BEAM groups, respectively. At 3 years, progression-free survival (PFS) was significantly higher in the BeEAM than in the BEAM group (84% [73-96] vs. 63% [51-79], p = 0.03). The overall survival was not statistically different between the two groups (p = 0.2). In multivariable analysis, BeEAM regimen remained associated with higher PFS (HR = 0.377, 95% CI, 0.146-0.970; p = 0.043). Subgroup analyses in patients treated with prior rituximab-aracytine induction alone showed that BeEAM improved the PFS compared with BEAM regimen (p = 0.04). Despite the high rate of acute renal failure KDIGO III (32%), treatment-related mortality was not increased with the BeEAM regimen. A prospective randomized trial will be necessary to confirm the beneficial effect of the BeEAM regimen in MCL patients undergoing ASCT.


Bone Marrow Transplant.. 2020 Jan 17;: